Topics
High-grade gliomas | Treatment | Targeted therapy | Bevacizumab
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Bevacizumab
Liao Y, Bai X, Cao Y, Zhang
M.
Effect
of low-dose bevacizumab on health-related quality of life in
patients with recurrent high-grade glioma: A retrospective
clinical study.
J
Clin Neurosci.
2024 Jan 25;120:196-203. doi: 10.1016/j.jocn.2024.01.018? PMID:
38277995. Observational study. ˍ
Bai X, Xing H, Feng M, Ma W, Wang S.
Dose
and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A
Retrospective Study.
Cancer
Manag Res. 2024 Nov 16;16:1617-1626. doi:
10.2147/CMAR.S481289. PMID:
39575164. Observational study. ˍ
Henriksen OM, Maarup S, Hasselbalch B, Poulsen HS, Christensen IJ,
Madsen K, Larsen VA, Lassen U, Law I.
Magnetic
resonance imaging and o-(2-[18F]fluoroethyl)-l-tyrosine
positron emission tomography for early response assessment of
nivolumab and bevacizumab in patients with recurrent high-grade
astrocytic glioma.
Neurooncol
Adv. 2024 Oct 24;6(1):vdae178. doi:
10.1093/noajnl/vdae178. PMID:
39659835. Interventional study. ˍ
Lim S, Clarke NH, Maloney SL, Sener UT, Caron SJ, Kizilbash SH,
Campian JL, Neth BJ, Carabenciov ID, Uhm J, Ruff MW.
Bevacizumab
exerts dose-dependent risk for intracranial hemorrhage in patients
with malignant gliomas.
J
Neurooncol. 2025 Jan 2. doi:
10.1007/s11060-024-04916-8. PMID:
39747716. Observational study˰
ˍ
Sahebjam S, Raval RR, Forsyth PA, Enderling H, Tran ND, Arrington
JA, Macaulay R, Perlow HK, Palmer JD, Ghose J, Rajappa P, Giglio
P, Li Z, Etame AB, Mokhtari S, Cruz-Chamorro RJ, Bhandari M, Thapa
R, Robinson TJ, Chen DT, Yu HM.
Phase
1 trial of hypofractionated stereotactic re-irradiation in
combination with nivolumab, ipilimumab, and bevacizumab for
recurrent high-grade gliomas.
Neurooncol
Adv. 2025 Feb 8;7(1):vdaf033. doi:
10.1093/noajnl/vdaf033. PMID:
40134851. Interventional study. ˍ
Aghedi M, Larijani A, Bagheri AB, Rafiemanesh H, Saraee E, Mardi
S, Shirani M.
Efficacy of combined
therapy with gamma knife radiosurgery and bevacizumab on survival
outcomes in patients with recurrent high-grade glioma: a
systematic review and meta-analysis.
Neurosurg
Rev. 2025 May 29;48(1):459. doi:
10.1007/s10143-025-03632-9. PMID:
40439764.
Review;
Meta-Analysis.
ˍ
Kroon LL, Dieleman EMT, Keil VC, van Barreveld M, Dijkgraaf MGW,
Topff L, Wagemakers SN, Snijders TJ, Vos MJ, Koekkoek JAF,
Stalpers LJA, de Vos FYFL, Brandsma D.
Bevacizumab
for symptomatic cerebral radiation necrosis after radiation of
high-grade glioma or brain metastases - when and for whom?
Neurooncol
Pract. 2025 Jun 5;12(5):747-762. doi:
10.1093/nop/npaf059. PMID:
41080204. Review. ˍ
Liu PC, Kuo CY, Chen YW, Lin CF, Lin SC, Chang FC, Chen MT, Wu JC,
Lee YY.
Bevacizumab alternating
chemotherapy for improving the survival of patients with recurrent
high-grade glioma.
Neurooncol
Adv. 2025 Jul 18;7(1):vdaf157. doi:
10.1093/noajnl/vdaf157. PMID:
40746950. Observational study. ˍ
Xuexue B, Chengrui Y, Ma W, Ming F, Chao W.
Predictive
role of MGMT and IDH status in the efficacy of bevacizumab for
high-grade glioma: a retrospective study.
Front
Oncol. 2025 Aug 25;15:1634892. doi:
10.3389/fonc.2025.1634892. PMID:
40927528. Observational study. ˍ
Yan C, Bai X, Wu C, Ma W, Feng M.
Correlation
between MGMT methylation and the efficacy of bevacizumab in
high-grade glioma.
Front
Oncol. 2025 Sep 2;15:1644934. doi:
10.3389/fonc.2025.1644934. PMID:
40963873. Observational study. ˍ
Sucuoğlu İşleyen Z, Seçmeler Ş, Sakin
A, Cihan Ş, Beşiroğlu M, Kahraman S, Karakurt
Eryılmaz M, Zeynelgil E, Çalışkan Yıldırım
E, Kut E, Şengül N, Paksoy Türköz F, Alan Ö,
Özkul Ö, Işık S, Yılmaz F, Gülmez A,
Türker S, Karakaya G, Günaldı M, Özer L, Aksoy
A, Karataş F, Sakalar T, Demirtaş Esmer D, Teker F,
Demir N, Dülgar Ö, Turhal S, Türk HM, Ertürk
K, Çelik E, Atcı MM.
Evaluation
of the efficacy and tolerability of bevacizumab-based treatments
in recurrent primary brain tumors: a multicenter real-world
Turkish Oncology Group (TOG) study.
BMC
Cancer. 2026 Feb 14;26(1):347. doi:
10.1186/s12885-026-15725-9. PMID:
41691201. Observational study. ˍ